Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Biochimie ; 75(3-4): 303-8, 1993.
Artigo em Inglês | MEDLINE | ID: mdl-8507691

RESUMO

A group of genetically determined peroxisomal diseases is characterized by both multiple enzymatic deficiencies and abnormal structural features of the organelle. The primary cause of the phenotypes is likely to involve peroxisome assembly impairment. Complementation analyses performed on fibroblasts of patients revealed the existence of at least eight groups that do not reflect the clinical classifications. Recently, the use of experimental models led to the identification of a gene encoding for a peroxisomal membrane protein (PAF-1) in which a mutation was associated with the altered phenotype in a complementation group of the Zellweger syndrome (paradigm of these diseases). Also revealed in Zellweger probands are mutations of a gene encoding another peroxisomal protein (PMP70).


Assuntos
Microcorpos/fisiologia , Animais , Células CHO , Cricetinae , Enzimas/deficiência , Teste de Complementação Genética , Humanos , Proteínas de Membrana/genética , Microcorpos/enzimologia , Microcorpos/patologia , Mutação , Fator 2 da Biogênese de Peroxissomos , Fenótipo , Síndrome de Zellweger/genética
2.
J Biol Chem ; 274(30): 21457-63, 1999 Jul 23.
Artigo em Inglês | MEDLINE | ID: mdl-10409710

RESUMO

Platelet-derived growth factor (PDGF) receptors (PDGFRs) are membrane protein-tyrosine kinases that, upon activation, become tyrosine-phosphorylated and associate with numerous SH2 domain-containing molecules involved in mediating signal transduction. In Rat-2 fibroblasts, we have characterized the phosphorylation of the beta-PDGFR following its activation by PDGF. In contrast to tyrosine phosphorylation, which was transient and returned to near basal levels by 30 min, PDGF-stimulated Ser/Thr phosphorylation of the beta-PDGFR was increased by 5 min and remained elevated after 30 min. In vivo, after 5 min of PDGF stimulation, serine phosphorylation of the beta-PDGFR was greatly reduced by CKI-7, a specific inhibitor of casein kinase I (CKI). In vitro, recombinant CKI-gamma2 phosphorylated the ligand-activated beta-PDGFR on serine residues in a CKI-7-sensitive manner and resulted in a marked inhibition of the receptor's autophosphorylating activity. Furthermore, in Rat-2 fibroblasts, expression of hemagglutinin epitope-tagged active CKI-gamma2 resulted in a dramatic decrease in the tyrosine phosphorylation state of the beta-PDGFR in response to PDGF, consistent with receptor inactivation. Our data suggest that upon PDGF stimulation, CKI-gamma2 is activated and/or translocated in proximity to the beta-PDGFR, whereby it phosphorylates the beta-PDGFR on serine residues and negatively regulates its tyrosine kinase activity, leading to receptor inactivation.


Assuntos
Fibroblastos/metabolismo , Proteínas Quinases/metabolismo , Receptores do Fator de Crescimento Derivado de Plaquetas/metabolismo , Animais , Caseína Quinases , Linhagem Celular , Ligantes , Fosforilação , Ratos , Receptor beta de Fator de Crescimento Derivado de Plaquetas , Serina , Transdução de Sinais
3.
Biochem Genet ; 34(3-4): 77-91, 1996 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-8734409

RESUMO

Although peroxisomes are ubiquitous, differences in the number of organelles and in the expression of associated metabolic activities are observed, depending on the cell type. To investigate the control of peroxisomal activity in connection with cell differentiation, we constructed hybrids between two types of cells whose histogenetic origins dictate significant differences in peroxisomal activities: hepatoma cells and fibroblasts, with high and low expression, respectively, of peroxisomal functions. In these hybrids, extinction of the elevated activities that characterize liver cells is observed, in parallel with the well-documented extinction of differentiated functions. This suggests the existence in fibroblasts of a negative trans-acting regulation.


Assuntos
Neoplasias Hepáticas Experimentais/metabolismo , Microcorpos/metabolismo , Acetil-CoA C-Acetiltransferase/genética , Actinas/genética , Acil-CoA Oxidase , Animais , Catalase/metabolismo , Diferenciação Celular , Resistência a Medicamentos , Ácidos Erúcicos/metabolismo , Ácidos Erúcicos/farmacologia , Fibroblastos/citologia , Fibroblastos/metabolismo , Humanos , Células Híbridas , Neoplasias Hepáticas Experimentais/patologia , Camundongos , Microcorpos/efeitos dos fármacos , Oxirredução , Oxirredutases/genética , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Ratos , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa